Aims
-
Identify molecular alterations that drive the development, progression, and recurrence of adult and childhood brain tumors.
-
Develop and test immunotherapies by leveraging innate and adaptive immune responses in brain tumors.
-
Accelerate translation of new therapies through innovative clinical trial designs and delivery approaches.
-
Advance understanding and treatment of brain metastases using expertise from primary brain tumor research.
The Neuro‑Oncology Program advances research and clinical innovation focused on tumors of the brain and central nervous system, which remain among the most challenging cancers to diagnose and treat. The program brings together basic science and clinical experts in epidemiology, molecular biology, immunotherapy, clinical research, and model development to study inherited and acquired molecular changes that influence tumor initiation, progression, and recurrence. Using genomic, epigenomic, transcriptomic, and immunologic approaches, investigators deepen understanding of brain tumor biology and develop improved laboratory models that inform new therapeutic strategies.
A major emphasis of the program is the development and evaluation of new treatment approaches, including immunotherapies, advanced delivery methods, and trial designs that accelerate the testing of emerging therapies. The program also studies tumors that spread to the brain from other parts of the body, applying insights from primary brain tumor research to improve detection and management of metastatic disease. Through coordinated research efforts, shared platforms, and multidisciplinary groups, the Neuro‑Oncology Program works to advance understanding of brain tumors, improve therapeutic options, and reduce the overall impact of these diseases.
